KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Minority Interest (2019 - 2025)

Royalty Pharma's Minority Interest history spans 7 years, with the latest figure at $3.2 billion for Q4 2025.

  • For Q4 2025, Minority Interest fell 4.65% year-over-year to $3.2 billion; the TTM value through Dec 2025 reached $3.2 billion, down 4.65%, while the annual FY2025 figure was $3.2 billion, 4.65% down from the prior year.
  • Minority Interest for Q4 2025 was $3.2 billion at Royalty Pharma, up from $3.2 billion in the prior quarter.
  • Across five years, Minority Interest topped out at $5.0 billion in Q1 2021 and bottomed at $3.1 billion in Q1 2025.
  • The 5-year median for Minority Interest is $3.5 billion (2023), against an average of $3.8 billion.
  • The largest annual shift saw Minority Interest decreased 19.38% in 2023 before it dropped 1.67% in 2024.
  • A 5-year view of Minority Interest shows it stood at $4.5 billion in 2021, then fell by 12.85% to $3.9 billion in 2022, then decreased by 8.71% to $3.6 billion in 2023, then decreased by 4.55% to $3.4 billion in 2024, then dropped by 4.65% to $3.2 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Minority Interest are $3.2 billion (Q4 2025), $3.2 billion (Q3 2025), and $3.2 billion (Q2 2025).